Aclaris Therapeutics joins the Nasdaq Biotechnology Index, enhancing its visibility in the biopharmaceutical sector.
Quiver AI Summary
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, announced its inclusion in the Nasdaq Biotechnology Index, effective December 19, 2025. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical companies on the Nasdaq Stock Market, requiring eligible companies to meet specific criteria such as market capitalization and trading volume. Aclaris is recognized for its innovative pipeline aimed at addressing unmet patient needs in immuno-inflammatory conditions and continues to advance its research and development efforts.
Potential Positives
- Aclaris Therapeutics has been added to the Nasdaq Biotechnology Index, highlighting its credibility and recognition in the biotechnology sector.
- Inclusion in the Nasdaq Biotechnology Index may attract more institutional investors and analysts, potentially increasing the company’s visibility and stock liquidity.
- The addition to the index reflects the company's compliance with high standards, including market capitalization and trading volume, which may instill confidence in current and potential investors.
Potential Negatives
- Being added to the Nasdaq Biotechnology Index may highlight a lack of investor confidence if market conditions suggest that it was added due to lower hurdles rather than robust performance metrics.
- The announcement does not provide any information on the company's financial performance or product pipeline status, which could raise concerns among investors about the company's ongoing viability.
- As a clinical-stage company, the reliance on research and development leaves Aclaris vulnerable to the uncertainties and risks associated with drug development, which are not addressed in this release.
FAQ
What is Aclaris Therapeutics known for?
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for immuno-inflammatory diseases.
When was Aclaris added to the Nasdaq Biotechnology Index?
Aclaris was added to the Nasdaq Biotechnology Index effective at the close of trading on December 19, 2025.
What does the Nasdaq Biotechnology Index track?
The Nasdaq Biotechnology Index tracks the performance of securities listed on The Nasdaq Stock Market that are classified as biotechnology or pharmaceutical.
What are the eligibility requirements for the Nasdaq Biotechnology Index?
Companies must meet criteria such as minimum market capitalization, average daily trading volume, and public company seasoning to qualify for the NBI.
Where can I find more information about Aclaris Therapeutics?
You can visit Aclaris Therapeutics' website at www.aclaristx.com or follow them on social media platforms like X and LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACRS Hedge Fund Activity
We have seen 43 institutional investors add shares of $ACRS stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,666,667 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,626,667
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,349,160 shares (-45.2%) from their portfolio in Q3 2025, for an estimated $8,263,404
- MILLENNIUM MANAGEMENT LLC removed 2,282,922 shares (-59.5%) from their portfolio in Q3 2025, for an estimated $4,337,551
- AMERIPRISE FINANCIAL INC added 1,277,817 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,427,852
- BOLLARD GROUP LLC added 1,225,476 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,328,404
- MONASHEE INVESTMENT MANAGEMENT LLC removed 888,888 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,262,220
- GOLDMAN SACHS GROUP INC added 799,479 shares (+510.6%) to their portfolio in Q3 2025, for an estimated $1,519,010
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACRS Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/25/2025
To track analyst ratings and price targets for $ACRS, check out Quiver Quantitative's $ACRS forecast page.
$ACRS Price Targets
Multiple analysts have issued price targets for $ACRS recently. We have seen 2 analysts offer price targets for $ACRS in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $16.0 on 10/20/2025
- Biren Amin from Piper Sandler set a target price of $6.0 on 07/10/2025
Full Release
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025.
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
For more information about the Nasdaq Biotechnology Index, please visit this link .
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]
